Bernstein analysts say AstraZeneca's strong R&D pipeline and breadth make a prolonged downturn like Roche's 2022-2025 experience unlikely. They trim target to 198 pounds from 200 pounds. Shares up 1% to 120.80 pounds.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
